Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
Related Content
Study data show parental delay is biggest factor in late retinoblastoma diagnosis
August 24th 2025

Study data show parental delay is biggest factor in late retinoblastoma diagnosis

ROP: Treating and preventing blindness in preterm babies
August 24th 2025

ROP: Treating and preventing blindness in preterm babies

Japanese researchers link outdoor time to rapid increase in choroidal thickness
August 24th 2025

Japanese researchers link outdoor time to rapid increase in choroidal thickness

Managing a changing landscape of IRD pediatric cases
August 24th 2025

Managing a changing landscape of IRD pediatric cases

Children with ADHD may be less likely to develop myopia, study suggests
August 24th 2025

Children with ADHD may be less likely to develop myopia, study suggests

Study links secondhand smoke exposure to increased myopia risk in children
August 24th 2025

Study links secondhand smoke exposure to increased myopia risk in children

© 2025 MJH Life Sciences

All rights reserved.